LSPN Connect: Protecting biologics at home and abroad

Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

Americas

LSPN 19: Mayo has led us down the rabbit hole, says lawyer

26 April 2019 There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

LSPN Connect: Protecting biologics at home and abroad

More on this story

Editor's picks

Editor's picks

More features